PL4199946T3 - Agoniści receptora crf2 i ich zastosowanie w terapii - Google Patents

Agoniści receptora crf2 i ich zastosowanie w terapii

Info

Publication number
PL4199946T3
PL4199946T3 PL21777954.5T PL21777954T PL4199946T3 PL 4199946 T3 PL4199946 T3 PL 4199946T3 PL 21777954 T PL21777954 T PL 21777954T PL 4199946 T3 PL4199946 T3 PL 4199946T3
Authority
PL
Poland
Prior art keywords
therapy
application
receptor agonists
crf2 receptor
crf2
Prior art date
Application number
PL21777954.5T
Other languages
English (en)
Inventor
Stephane Illiano
Laurence LUCATS
Laetitia LEDEIN
Philippe Beauverger
Philip Janiak
Marie-Laure Ozoux
Nis Halland
Ziyu Li
Ralf Elvert
Andreas Evers
Elisabetta Bianchi
Alessia Santoprete
Daniela ROVERSI
Martina TRIPEPI
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of PL4199946T3 publication Critical patent/PL4199946T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57509Corticotropin releasing factor [CRF] (Urotensin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2228Corticotropin releasing factor [CRF] (Urotensin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72Receptors; Cell surface antigens; Cell surface determinants for hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL21777954.5T 2020-08-19 2021-08-18 Agoniści receptora crf2 i ich zastosowanie w terapii PL4199946T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20315387 2020-08-19
PCT/EP2021/072923 WO2022038179A1 (en) 2020-08-19 2021-08-18 Crf2 receptor agonists and their use in therapy

Publications (1)

Publication Number Publication Date
PL4199946T3 true PL4199946T3 (pl) 2024-08-19

Family

ID=72615799

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21777954.5T PL4199946T3 (pl) 2020-08-19 2021-08-18 Agoniści receptora crf2 i ich zastosowanie w terapii

Country Status (16)

Country Link
US (1) US20250243255A1 (pl)
EP (2) EP4199946B1 (pl)
JP (1) JP7832927B2 (pl)
KR (1) KR20230051583A (pl)
CN (1) CN116472053A (pl)
AU (1) AU2021328673A1 (pl)
CA (1) CA3192032A1 (pl)
ES (1) ES2988026T3 (pl)
HR (1) HRP20240906T1 (pl)
HU (1) HUE066991T2 (pl)
IL (1) IL300464A (pl)
IS (1) IS3063B (pl)
MX (1) MX2023002087A (pl)
PL (1) PL4199946T3 (pl)
WO (1) WO2022038179A1 (pl)
ZA (1) ZA202301784B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
EP4234574A1 (en) * 2022-02-23 2023-08-30 Corteria Pharmaceuticals Crf2 receptor agonists and their use in therapy
WO2025104264A1 (en) 2023-11-17 2025-05-22 Gubra A/S Hcrhr2 selective polypeptides
TW202544027A (zh) * 2024-04-19 2025-11-16 美商紐羅克里生物科學有限公司 促皮質素釋放因子受體2(crfr2)促效劑
WO2025230248A1 (ko) * 2024-04-30 2025-11-06 한미약품 주식회사 Crf2 수용체 작용제와 그 아실화 결합체의 용도
WO2026064495A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof
WO2026064486A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008047241A2 (en) * 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
JP5721432B2 (ja) 2007-08-15 2015-05-20 ノボ・ノルデイスク・エー/エス アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
CN104356224A (zh) 2014-10-24 2015-02-18 杭州阿德莱诺泰制药技术有限公司 一种制备萨摩鲁泰的方法
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
WO2019140030A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy

Also Published As

Publication number Publication date
KR20230051583A (ko) 2023-04-18
HRP20240906T1 (hr) 2024-10-11
EP4199946A1 (en) 2023-06-28
ZA202301784B (en) 2024-01-31
EP4435001A3 (en) 2024-10-09
WO2022038179A1 (en) 2022-02-24
IL300464A (en) 2023-04-01
HUE066991T2 (hu) 2024-09-28
MX2023002087A (es) 2023-03-23
AU2021328673A1 (en) 2023-03-30
JP2023541798A (ja) 2023-10-04
CN116472053A (zh) 2023-07-21
JP7832927B2 (ja) 2026-03-18
EP4199946C0 (en) 2024-06-05
IS3063B (is) 2025-06-15
US20250243255A1 (en) 2025-07-31
EP4435001A2 (en) 2024-09-25
ES2988026T3 (es) 2024-11-19
CA3192032A1 (en) 2022-02-24
EP4199946B1 (en) 2024-06-05

Similar Documents

Publication Publication Date Title
PL4199946T3 (pl) Agoniści receptora crf2 i ich zastosowanie w terapii
EP4247801A4 (en) 3-AMINO PYRROLIDINE AND MACROCYCLIC PIPERIDINE OREXIN RECEPTOR AGONISTS
PL4482578T3 (pl) Agoniści receptora crf2 i ich zastosowanie w terapii
IL282487A (en) Tyk2 inhibitors and uses thereof
IL284210A (en) Compounds that participate in cooperative binding and uses thereof
SI3658557T1 (sl) Zaviralci TYK2 in njihova uporaba
DK4219487T5 (da) Glp-1-receptoragonister og anvendelse heraf
EP3858856A4 (en) ANTI-B7-H3 MONOCLONAL ANTIBODY AND ITS USE IN CELL THERAPY
DK3707159T5 (da) Hidtil ukendte modificerede t-cellereceptorer og immunterapi med anvendelse deraf
CL2011003160A1 (es) Compuestos derivados de heterociclicos, moduladores cb2; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades reumaticas, autoinmune, inflamatorias, dolor, entre otras.
PL3806898T3 (pl) Antagonista gremlin-1 do zastosowania w leczeniu nowotworu
EP4212524A4 (en) Cd73 inhibitor and application thereof in medicine
IL311837A (en) Compositions targeting bcma and methods of use thereof
DK3423496T3 (da) Ikke-antagonistiske antistoffer rettet mod alfakæden i IL7-receptorens ekstracellulære domæne og anvendelse deraf i kræftbehandling
IL312330A (en) Tyk2 degraders and uses thereof
PL3768284T3 (pl) Kompozycje z fageliny entrecoccus do zastosowania w terapii
EP4444324A4 (en) MODIFIED T CELL RECEPTORS AND THEIR USES
EP4326771A4 (en) CHIMERIC CYTOKINE RECEPTORS AND THEIR USES IN CELLULAR THERAPIES
SI4301770T1 (sl) Dolgodelujoči agonisti amilinskih receptorjev in njihova uporaba
EP4458844A4 (en) Anti-coronavirus polypeptide, its derivatives and its use
SI3788187T1 (sl) Kombinirana naprava za elektropredenje in mikroekstruzijo
SI3349778T1 (sl) Farmacevtska asociacija agonista receptorja rastnega faktorja in zaviralca adhezijskega proteina za pretvorbo neoplastične celice v ne-neoplastično celico in njena uporaba
IL282926A (en) T cell receptors specific for mesothelin and their use in immunotherapy
PL4161528T3 (pl) Kombinacja ruksolitynibu z incb057643 do stosowania w leczeniu nowotworów mieloproliferacyjnych
IL312874A (en) Pharmaceutical composition and use thereof